HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK & Canada Expand Scope Of Mutual Recognition Of GMP Inspections

Executive Summary

Drug importers can benefit from UK and Canada’s decision to recognize outcomes of each other’s manufacturing inspections conducted in foreign jurisdictions.

You may also be interested in...



UK/Canada Deal Lets Drug Agencies Avoid Brexit-Related Trade Disruption

An interim trade deal between the UK and Canada means that the regulators in these countries will carry on accepting each other’s batch testing and GMP certificates.

Global Medtech Guidance Tracker: September 2022

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-two documents have been posted on the tracker since its last update.

€5m Initiative To Help EU Member States Cooperate On Trial Safety Assessments

An EU funded project is to help national competent authorities cooperate on the safety assessment of clinical trials as required under the Clinical Trial Regulation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel